AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual Meeting
OCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM”…